Financial writer recommends Crispr Therapeutics AG as a strong buy due to cash position, drug pipeline, and promising ...

Australian researchers have successfully introduced an improved version of Cas12a gene-editing enzyme in mice.

Cas9, the first Cas protein repurposed for cutting DNA, introduces double-strand breaks that recruit DNA repair machinery. Despite its successes, the CRISPR-Cas9 system has several limitations, ...

Get Instant Summarized Text (Gist) CRISPR nucleases, Cas9 and Cas12, have been engineered to evade immune detection, addressing a key challenge in CRISPR-based therapies. By identifying and ...

This streamlined licensing option enables a broader spectrum of innovators to access CRISPR/Cas9 intellectual property ... high-throughput screening and functional genomics. Prof Emmanuelle ...

It's clear though that these companies need time. Even with the only approved CAS9 based treatment out there, CRISPR is still years away from achieving its potential. In a recent update to ...

CRISPR-Cas9 is comprised of two parts ... The company is actively screening for the Phase 3 HAELO study for NTLA-2002. Intellia CEO John Leonard commented, “With three active Phase III studies ...

Australian cancer researchers are the first to establish a next-generation gene-editing tool for modeling and interrogating human disease.